Objective To determine clinical and histopathological factors in patients with cervical carcinoma tumors smaller than 2 cm in order to identify those who could be operated less extensively with preservation of reproductive organs and lower morbidity. Material and methods We retrospectively reviewed the records of patients with cervical cancer and a maximum tumor diameter of 2 cm who were qualified to primary surgery in the years [2001] [2002] [2003] [2004] [2005] [2006] [2007] at the Department of Gynecologic Oncology, Cancer Center in Warsaw.
Results From the group of 110 operated patients, 96 were included into retrospective analysis. Within the analyzed group the infiltration of the parametrium was found in 4 women (4,2%). All had squamous cell cancer; stage IB, grade G3. One patient had a tumor of 1,5 cm and 3 patients had tumors of 2 cm. The involvement of lymph nodes was observed in 3 patients with squamous cell carcinoma: in one case the tumor was intermediate grade (G2) and in two cases low grade (G3). The lymph nodes were involved only in patients with tumors greater than 0.5 cm. The lymphatic vessels were infiltrated in 14 patients (14,7%): in 12 with squamous cell cancer and in 2 with adenocarcinoma. The diameter of the tumor was 0.5-1 cm in 4 women, 1-1.4 cm in 3 women and 1.5-2 cm in the majority (7 women accounted for 29% of all patients in that group). No infiltration of the blood vessels could be seen in all 30 women with tumors smaller than 0,5 cm. We found a statistically significant relationship between the size of the tumor and the incidence of vessel infiltration (p=0.024). Conclusion In patients with cervical cancer when tumor diameter not exceed 5 mm surgery preserving reproductive organs is effective and safe. In patients with tumor diameter not exceeding 1 cm the resection of parametrium seems unjustified.
Support None
The use of letrozole in breast cancer patients undergoing fertility preservation IVF treatment is associated with similar oocyte yield and lower edtradiol levels Objective Chemotherapy-related amenorrhea is a frequent side effect observed in young breast cancer patients (pts). Studies in mice revealed that chemotherapy-induced gonadal toxicity may be due to vascular damage. We followed young breast cancer pts prospectively for ovarian parameters and related symptoms before, during and after chemotherapy. Methods Young female pts (<43 years) with localized breast cancer undergoing adjuvant or neoadjuvant anthracycline or taxane-based chemotherapy were evaluated by transvaginal ultrasound prior to initiation of chemotherapy and immediately after the cessation of chemotherapy. Doppler-flow velocity indices of the ovarian vasculature ((resistance index (RI), pulsatility index (PI)) and size measurements were visualized. Hormonal profile, anti-Mullerian hormone (AMH) and menopausal symptoms were assessed at the same time points. Results Twenty breast cancer pts were enrolled into the study. Median age was 34±5.24 years. Ovarian blood flow was significantly reduced immediately following chemotherapy: RI decreased by 52.5% (P<0.0001) and PI by 24.2% (p=0.01) after treatment. Mean ovarian measures decreased by 19.08% (p=0.018). Patients who were treated with sequential chemotherapy experienced further reduction in ovarian blood flow and ovarian size after the second sequence. AMH dropped dramatically in all the patients following treatment (P<0.001). Hormonal profile depicted a post-menopausal profile for most patients, accompanied by related symptoms, Conclusion Our results may imply a mechanism of chemotherapy-induced ovarian toxicity, manifested by a decreased ovarian blood flow accompanied by a reduction in ovarian size. Based upon our former preclinical studies, we assume this may derive from an acute insult to the ovarian vasculature.
Support institutional funding

Ovarian response to stimulation treatment in oncologic patients
Objective To evaluate the ovarian response to controlled ovarian hyperstimulation in women with cancer (study group) and compare it to the expected response in a standard In Vitro Fertilization (IVF) population. Materials and methods From 2007 to 2011, 28 women with cancer underwent controlled ovarian hyperstimulation for embryo or oocyte cryopreservation. All patients were on an antagonist protocol, stimulation was performed with rFSH and letrozole was added for patients with breast cancer. In four cases, stimulation started on the lutheal phase after GnRH antagonist administration for lutheolysis. The following outcome measures were collected: the number of oocytes retrieved, total gonadotrophin consumption and duration of stimulation. The expected ovarian response was calculated with an age specific normogram for the number of retrieved oocytes, which was built including 7128 first cycles (preimplantational diagnosis and polycystic ovaries excluded). The Z score was used to compare the number of retrieved oocytes between the study group and the standard IVF population. Results The study group had a mean age of 32.8± 4.6 years, the mean total gonadotrophin consumption was 2317±961 IU and the mean duration of stimulation was 9.61 ± 2 days. The mean number of retrieved oocytes was 14±10.5. After applying the Z-score to compare the number of retrieved oocytes between both groups, we did not observe an statistically significant difference (Z score −0.13 CI 95 [−0.61-0.35 
]).
Conclusions There is no evidence to conclude that oncologic patients have a different ovarian response than our standard IVF population. Even though the comparison was not established with healthy controls, the normogram used was built with a high number of standard cases. Support None Fertility preservation in women undergoing treatment for breast cancer in the UK: questionnaire study Objective Patients should be informed of the risk of infertility and offered referral to discuss fertility preservation options before systemic treatment commences. Our aim was to examine the referral practices of healthcare professionals who treat women with breast cancer in the UK, and to investigate their understanding and knowledge of the fertility preservation options available. Design Questionnaire study. An invitation to participate in a confidential, online questionnaire was emailed to surgeons, oncologists and clinical nurse specialists who manage patients with breast cancer in the UK. Results 306 questionnaires were received. Respondents had referred a median average of 3 breast cancer patients for fertility preservation in the last year. Factor which influenced whether fertility preservation options were discussed with a patient included: age (77%), final tumour/nodes/metastasis (TNM) status (37.9%); concern that chemotherapy would be delayed (37.3%); whether the patient had children (33.5%) or a partner (24.7%); oestrogen receptor expression (22.6%), lack of knowledge regarding the available options (20.9%) and concern that the success of cancer treatment would be compromised (19.8%). 27% did not know whether fertility preservation was available for their patients on the NHS. 49.4% of respondents said that GnRH agonists were used for fertility preservation outside the setting of a clinical trial. Knowledge regarding the available options varied significantly, with Consultant oncologists more likely to know than Consultant surgeons or clinical nurse specialists (p<0.05). Conclusions Many healthcare professionals have incomplete knowledge regarding the local arrangements for fertility preservation for patients with breast cancer. This may result in patients receiving inadequate or conflicting information regarding fertility preservation.
Support Royal Free Hospital Charity
Evaluation of breast cancer effect on ovarian reserve
Objectives Breast cancer (BC) is the most common indication for ovarian tissue cryopreservation (OTC). However, it is unknown if this oncologic disease affects ovarian reserve. The aim of this study was to evaluate the effect, if any, of breast cancer on ovarian reserve. Matherial and methods Biopsies from the right ovarian cortex were obtained from 60 women whom participated in the Valencia Programme for Fertility Preservation. No one of these patients underwent ChT prior to ovarian cortex extraction. Forty-five of these women had BC (mean age 29.2±4.7 yrs, range:19-37) and fourteen women had a nonmalignant disease (mean age 25.6±4.7 yrs, range: 19-36). Histological and morphometric analysis were carried out to evaluate the follicular density (FD, follicles/mm2). The Anti-Müllerian hormone (AMH, μg/L), FSH and LH (mU/ml) serum levels of each patient were measured. Results There was not significant difference between the FD and the AMH levels of BC (2.5±4.2; 1.6±1.4) patients compared to the controls (3.6±4.1, 1.7±0.9). However a trend to decrease the media of FD in BC patients was observed. Conclusions Breast cancer by itself decreased the follicular density and the AMH levels but not in a significant manner. Support Objective To study the 'burn out' mechanism involved in chemotherapy-induced ovarian reserve deplition. To investigate the mechanism and potential role of AS101 cotreatment to prevent follicle loss. Materials and methods Balb/c 8w female mice received single doses of 75-150 mg/kg Cyclophosphamide (Cy), or 4 weekly doses of 75 mg/kg Cy with or without alternate day 10 μg AS101 1w prior -1w post Cy. Postnatal (5 d) mice received single 150 mg/kg Cy dose. Ovaries were histologically fixed and differential follicle counts conducted, and plasma AMH was measured (ELISA). TUNEL staining was used to demonstrate apoptosis and Ki67 staining documented proliferation. Protein analysis measured phosphorylation of activation proteins Akt, mTORC1, rpS6, and the suppressor protein FOXO3a. Ovulation rate 8w post last Cy was evaluated by counting the total number of Corpus lutei. Breast cancer cell lines MCF-7 and MDA-MB 231 were treated with increasing concentrations of active Cy metabolite with/ without AS101 0.1 μg/ml and 0.5 μg/ml respectively. Cell viability was assessed with the MTT viability assay. Results Co-treatment with AS101 during Cy administration significantly resulted in higher number of PMF and prevented the fall in AMH plasma levels. The increased number of growing follicles post Cy and the increased ratio of growing to PMF follicles that exist post Cy were significantly less in AS101 co treatment groups. TUNEL and Ki67 staining indicated that AS101 reduced apoptosis in growing follicles and decreased proliferation in PMF. AS101 reduced protein phosphorylation of Akt, mTOR, rpS6 and FOXO3a. Corpus lutei number in AS101 co-treated mice was higher than Cy alone. In both cancer-cell lines AS101 increased cell sensitivity to Cy with synergistic and additive effects. Conclusions Our results show that AS101 reduces follicle loss and protects ovarian reserve during Cy administration. The mechanism of AS101 protective activity is through inhibition of the PI3K/PTEN/AKT pathway responsible for accelerated PMF activation and burn-out. Moreover, AS101 does not reduce anti cancer Cy activity, rather it has additive and synergistic activity. We propose that AS101 could serve as a practical and economical agent for fertility preservation. These results hold great promise for female patients undergoing chemotherapy. Support Kahn foundation, Israel ministry of health, Israel cancer association Fertility preservation in cancer therapy (updated trend) Introduction The incidence of cancer in pre and post puperal women is about 8% , chemo and radiotherapy may induce transient or persistent amenorrhea and premature ovarian failure, this raises the need to preserve the fertility of oncological patient to allow a reproductive life after cancer remission ,her we report our experience in the period from 2008 to 2011 in many lines. 1 st line, comparing the efficiency of ovarian tissues cryopreservation, using a conventional slow freezing medium and a new media replacing sodium (autologous eye tears). 2 nd line, telomere elongation based on the fact that reproduction is proportional to telomere elongation. 3 rd line, uses of laparoscopy to inject substances in the ovary before and at the beginning of chemo and radiotherapy. 4 th line ,improving the fertility preservation by combinations of first cryo preservation of the ovarian tissue followed directly by ovarian stimulation . 5 th line, use of nanotechnology in animal experimentation, Material and methods For the 1 st line , small biopsies of ovarian cortical tissues collected during laparoscopy for non reproductive diseases who had given informed consent in participation in the study , cortical slices ( 1mm×3 mm× 8 mm) were cryopreserved in conventional and autologus eye tears as a new media is used . Immune-histo chemistry, for the apoptotic markers P63,P53,P21,and Apaf I and transmission electron microscopy (TEM), primordial and primary follicles were scored as grade 1(spherical oocyte ) evenly surrounded by granulosa cell , grade 2 spherical oocyte irregularly surrounded by granulosa cell, grade 3 , oocyte with altered morphology having granulosa cells with pyknotic nuclei. Regarding the 2nd line ,telomere elongation ,we used before chemotherapy and radiotherapy for cancer breast patient (N=15 ) protocol include bee honey, bee venom ,bee propolis ,melatonin, curcumin, CoenzymQ 10 and zamazm water ,starting 2 weeks before treatment and extending through treatment and one month after treatment measuring the telomere length in the study group and control (10 cases ) not taking the previous protocol ,telomere length is measured by specific quantitative PCR, telomere length is measured in whole blood ,this make an accurate proxy for telomere in the ovary . 3 rd line, by directly injecting peripheral blood mono-nuclear cells (N=10), bee venom (N=10) melatonin (N=10), cerebrolysine (N=10) in both ovaries and follow up for 1 month after the end of treatment measuring the ovarian reserve. 4 th line ten patient (study group) with breast cancer 25% of ovarian tissues were removed by laparoscopy and cryopreservation on the same day after surgery stimulation was initiated , mature follicle were aspirated ,oocyte were cryopreserved with or without fertilization by ICSI, outcome was compared with ten control receiving ovarian stimulation before chemotherapy without initial cryopreservation of ovarian tissue . As regard 5 th line, we use Nano gold particle in 10 mice and Nano silver in another 10 mice taken chemotherapy, ovarian biopsy was taken for detection of ovarian reserve Results A higher percentage of primordial and primary follicles endowed with normal morphology, absence of apoptotic markers and ultra structurally preserved follicles can be detected in human cortical tissue cryopreserved with autologous eye tears substituted media Statistically significance elongation of telomere in patient taking previous protocol than in non-intake P <0.05 regarding the 3 rd line: statistically significance increase in primordial follicles and ovarian reserve than control (P< 0.05), regarding the different media used no statistical difference between all media (P>0.05). Regarding the 4 th line, the combination of first preservation of ovarian tissue followed directly by ovarian stimulation resulted in a high quality of ovarian tissue and average number of oocyte with average fertilization potential without any complication, this new protocol, therefore allows for the first doubling the efficacy of fertility preservation before chemo and radio therapy within a time of only 2 weeks. Regarding the 5 th line: satisfactory ovarian reserve after Nano gold and Nano silver particles in experimental animals. Conclusion For the first time in literature we introduce autologous eye tears replacing sodium to improve cryopreservation of a human ovarian tissues ,telomere elongation to improve reproduction ,laparoscopic intra ovarian injection of PBMNCs ,bee venom ,cereberolysine, melatonin to improve the ovarian reserve ,and the combination of first cryoprteservation of ovarian tissue followed directly by ovarian stimulation ,allowing doubling the efficacy of the ovarian stimulation before chemo and radio therapy, Nano gold particles protect the ovarian follicle from radio and chemo therapy ,the strange in Nano gold and Nano silver particles is that ,by its use we reduce the radiation and chemotherapeutic doses Keyword Cryopreservation ,eye tears, telomere, melatonin, cerebrolysine , Nano gold, Nano silver particles.
Overcoming female infertility after pediatric cancer: what can we offer?
Objective To describe our pediatric programme for fertility preservation, including ovarian cryopreservation (OCP) and in vitro maturation plus cryopreservation of aspirated oocytes (IVM), in a single centre cohort of young girls with cancer. Material and methods Descriptive study. Clinical records of children that underwent OCP and IVM in our centre were analyzed. Time period: October 2008-September 2011. Explicit discussion with families and written consents were obtained, including assent of all transplanted minors. Results OCP was performed in 25 pediatric patients in the time period. Median age: 12.5 years (2.9-15). Underlying diseases: Acute lymphoblastic leukemia (7), acute myeloblastic leukemia (4), myelodysplastic syndrome (2), Ewing sarcoma (4), soft tissue sarcoma (1), Wilms tumour (1), disseminated medulloblastoma (1), Hodking disease (5). All of them were going to receive stem cell transplant, pelvic radiotherapy or high doses of alkylating agents. Partial or entire laparoscopic ovariectomy was carried out without surgical complications and in 2 cases contralateral ovariopexy was associated. The tissue was successfully obtained at the same time of other surgical procedures in 12 cases: venous central line insertion (VCLI) bone marrow aspirate (BMA), lumbar puncture (LP). Oncological planned treatment was started without any delay. Preoperative imaging, histological examination of fresh tissue, immune-histochemistry, polymerase PCR or RT-PCR were used for excluding ovarian infiltration and confirming the presence of primordial follicles in all of them. In 11 patients oocytes aspiration at the time of OCP was performed. We achieved in vitro maturation and cryopreservation in 2 cases (5.1 and 13.8 years). Conclusions In our experience OCP and IVM was safely and efficiently carried out. Close coordination between pediatric oncology, surgery and gynaecological teams was required to address practical and ethical issues in this vulnerable population.
Clinical outcomes following a letrozole/GnRH antagonist controlled ovarian stimulation protocol for breast cancer patients previously treated with chemo/radiation therapy Jack Y.J. Huang, Tomer Singer, Glenn Schattman, Owen Davis, Zev Rosenwaks
Objective Breast cancer patients previously treated with gonadotoxic chemo-and/or radiation therapy often experience infertility due to diminished ovarian reserve, requiring assisted reproductive techniques. We report the clinical outcomes of breast cancer survivors who underwent letrozole/GnRH antagonist controlled ovarian stimulation (COS) and fresh embryo transfer (ET). Materials and methods Breast cancer survivors who underwent letrozole/GnRH antagonist COS and fresh ET during the period of January 2008 to December 2009 were included. Letrozole/GnRH antagonist COS protocol involved daily administration of 5 mg letrozole from cycle day 2 until the day of hCG. Gonadotropins were started on day 4. GnRH antagonist was started when either the leading follicle reached 13 mm or estradiol (E2) >300 pg/ml. hCG was given when 2 follicles >18 mm mean diameter. Retrieval occurred 35 hours later. Main outcome measures were: peak E2 levels, endometrial stripe (ES) diameter, oocyte yield, and clinical pregnancy rate. Statistical analyses included X 2 and Mann-Whitney tests. Results 8 patients underwent 16 letrozole/GnRH antagonist COS cycles. The mean age was 40.9±2.6 years. The mean day 2 FSH and E2 were 9.1±2.2 mIU/ml and 40.9± 21.1 pg/ml respectively. The mean gonadotropin dose per day was 325.0±150.8 U. On the day of hCG, the mean ES measured 10.4±1.5 mm and mean E2 was 451.4±81.7 pg/ ml. In 6 cycles, the peak E2 was >400 pg/ml. 2 cycles were canceled due to poor response. The mean number of oocytes per retrieval was 8.2±4.1. Among 13 ET cycles, a mean of 2.7±0.9 embryos were transferred, resulting in 6 pregnancies (3 live births, 2 biochemical, 1 ectopic). Conclusions In selected breast cancer patients previously treated with surgical resection and adjuvant chemo/radiation treatments, a satisfactory pregnancy rate can be achieved following letrozole/GnRH antagonist COS and fresh ET, particularly in light of these patients' advanced mean age. Support Institutional
Evaluation of Hodgkin's disease (HD) effect on ovarian reserve
Novella-Maestre E, Teruel J, Roselló E, Pellicer A, Sánchez-Serrano M.
Objectives In our experience, HD is the second indication for ovarian tissue cryopreservation (OTC), after breast cancer. It is known the deleterious effect on spermatogenesis in males with HD, however, it is unknown if this disease affects ovarian reserve. The aim of this study was to evaluate the effect, if any, of HD on ovarian reserve. Matherial and methods Biopsies from the right ovarian cortex were obtained from 47 women whom participated in the Valencia Programme for Fertility Preservation. No one of these patients underwent ChT prior to ovarian cortex extraction. Thirty-tree of these women had HD (mean age 27.8 ±5.2 yrs, range: 16-38) and fourteen women had a non-malignant disease (mean age 25.6±4.7 yrs, range: 19-36). Histological and morphometric analysis was carried out to evaluate the follicular density (FD, follicles/mm2). The Anti-Müllerian hormone (AMH, μg/L), FSH and LH (mU/ml) serum levels of each patient were measured. Results There was not significant difference between the FD and the AMH levels of HD (2.4±4.6; 1.8±1.6) patients compared to the controls (3.6±4.1, 1.7±0.9). However a trend to decrease the media of FD in HD patients was observed. Conclusions HD by itself decreased the follicular density and the AMH levels but not in a significant manner. Support This work was supported by EVES 2008 grant and FIS PI08/1997 grant from the Spanish Government. None of the authors have any conflict of interest in relation to this work.
Fertility preservation during abdominal surgeries
Snchez-Serrano M, Teruel J, Novella-Maestre E, Pellicer A Objective To present a case illustrating the possibility of preserving fertility at abdominal surgeries, whether emergency or programmed. Materials and methods A 29 years old woman undergoing abdominal surgery, after failed medical treatment, with the diagnosis of Chrons disease and the presence of an adnexal mass. She had undergone 9 years earlier a right adnexectomy. The suspicious diagnosis then was a pelvic inflammatory disease, but the surgical piece examination was Crhons disease. The surgical findings at the second laparotomy were a frozen pelvis, the absence of right adnexa and an enlarged left ovary (aproximately 10x10cm), the falopian tube was not identifiable. The intervention included adhesiolysis, left adnexectomy, bowel ressection and ileostomy. The excised ovary was evaluated and the cortex was processed as usual for cryopreservation (1 mm thikness). The very large cortex piece was then divided in to two, one half was cryopreserved and the other one half transplanted in a pocket created beneath the abdominal rectus muscles. Titanium staples were placed for later localization. Results Twenty-one days after the implant, serum FSH level was 56.8 mIU/mL and antimllerian hormone (AMH) 3.66 ng/ mL. On day 37 a MRI showed the presence of growing follicles. The first menstruation occurred 66 days after implant and more than 5 years later the patient maintains regular menses with basal serum FSH level of 5.5 mIU/mL and AMH 1.45 ng/mL. So far the patient has not requested ART, logically neither the implantation of the frozen tissue. Conclusions Virtually it is always possible preserve fertility during abdominal surgery, even if ovary is implicated in the process. Support This work was supported by FIS PI08/1997 grant from the Spanish Government. No one of the authors have any conflict of interest in relation to this work
Evaluation of chemotherapy (ChT) effect on ovarian reserve
Objectives Ovarian tissue crypreservation (OTC) and autotransplantation are intended for women undergoing aggressive regimens of ChT and/or radiolotherapy. Main indications for the procedure are cancer and autoimmune disorders. The aim of this study was to evaluate the effect of ChT on ovarian reserve before OTC. Matherial and methods Right ovarian cortex biopsies were obtained from 20 women participating in the Valencia Programme for Fertility Preservation. Ten of these patients underwent ChT prior to ovarian cortex extraction (mean age 28.4±5.9 yrs, range:19-37): 5 breast cancer (ChTBC) and 5 Hodgkin disease (ChTHD). Ten patients: 5 breast cancer (BC) and 5 Hodgkin disease (HD) did not received any oncologic treatment prior to ovarian cortex extraction (mean age 28.2± 5.3 yrs, range: 20-37) . Histological/morphometric analysis was carried out to evaluate the total follicular density (FD), Primordial (PFD), secondary (SFD) and mature (MFD) follicular density, expressed as follicles/mm 2 . Anti-Müllerian hormone (AMH, μg/L) serum levels of each patient were measured. Results A significant decrease (P 0.05) in PFD and AMH was observed in ChTHD (0.3±0.2, 1.2±0.7) compared to HD patients (1.7±1.6, 2.2±0.9) but not significant difference was observed in ChTBC (0.4±0.9, 2.7±3.1) compared to BC (0.4±0.4, 2.1±1.7). A significant decrease (P 0.05) of FD, PFD and SFD was observed when the 10 patients that underwent chemotherapy (0.4±0.7; 0.4±0.7; 0.1±0.1) were compared with the 10 patients that did not received any oncologic treatment (1.1±1.3; 1.0±1.3; 0.1±0.1) but not significant differences were found in AMH levels. Conclusions ChT decreased significantly FD but did not affect AMH levels in BC patients neither in HD patients. These data should be taking into account when facing fertility preservation after ChT. Support Objective To evaluate oocyte yield in patients undergoing ovarian stimulation for fertility preservation prior to chemotherapy. Design A retrospective cohort study in a hospital-based academic medical center. Materials and methods A comparison between thirty-six women diagnosed with breast cancer and twenty healthy patients undergoing elective fertility preservation who presented for IVF in our center between Feb 2008 to Feb 2011. Main outcome measures were the number of oocytes harvested and cryopreserved. Results No statistically significant differences were observed between patients undergoing fertility preservation for breast cancer and those cryopreserving oocytes for social reasons with regard to age, BMI, amount of gonadotropins used, days of stimulation or endometrial thickness measured on day of HCG administration. Peak serum estradiol (E2) levels were significantly lower for women in the breast cancer group, mainly because this group used an aromatase inhibitor during stimulation. A trend towards a higher number of oocytes recovered was seen in the breast cancer patients although it did not reach statistical significance. Conclusions Our results suggest that the use of Letrozole for ovarian stimulation when compared with a standard IVF protocol, resulted in a similar oocyte yield with significantly lower estradiol levels. A larger prospective study analyzing the use of Letrozole in breast cancer patients is warranted. Objectives This study was designed to investigate the effects of a commonly used therapeutic agent (Busulfan) on spermatogenesis and male fertility. Materials and methods Seventy-five nude mice aged 5-8 weeks were examined and received a single 40 mg/kg dose of Busulfan (n=32) or no treatment (n=43). Seven mice were sacrificed from each group after 1 month and their body and testes weights were recorded. Testes were harvested and prepared for histological and immunohistological examinations. Germ cells and testicular somatic cells were identified using specific markers including VASA, cKit and LHR (Luteinizing Hormone Receptor). Some testes were dissociated and analyzed by flow cytometry for the germ cell marker VASA. The rest of the mice were kept for additional 3-7 months and were mated with female nude mice to test their post-chemotherapy fertility. Results Administration of a single 40 mg/kg dose of Busulfan had no adverse effect on body weight, however this dosage significantly (P<0.001) reduced the testes size. Histological examination confirmed the shrinkage of the testes due to Busulfan administration and revealed that the majority (82%) of seminiferous tubules in testicular cross sections were completely empty or contained incomplete spermatogenesis. Immunohistochemical localization of the germ cell markers VASA and c-Kit showed that most tubule cross sections were depleted of germ cells by Busulfan (p<0.0001). Moreover, flow cytometric analysis showed that the proportion of VASA-positive cells was significantly (P< 0.001) reduced after Busulfan treatment (Table) . In contrast, testicular somatic cells stained by LHR were not affected by Busulfan administration. Fifty-five percent of the mice that received Busulfan regained their fertility with some delay and produced pups by natural mating. The rest of the males could not conceive by natural mating. Conclusions A single dose of Busulfan depleted the majority of the germ cells from the testes but had no effect on body weight. Although half of the mice regained their fertility naturally with some delay, the remaining mice were unable to conceive naturally during the length of the study. Therefore to safeguard the fertility of male patients; steps should be taken to preserve fertility prior to chemotherapy. Support None. Results A 33 year-old Caucasian patient presenting a lower jaw medular mass and oral dysesthesia was initially diagnosed from cleaved-cell small lymphocytic lymphoma after biopsy of the mass. She was referred to our center to undergo ovarian cortex cryopreservation prior to chemotherapy. CT-Scan, MRI, blood panel and bone marrow biopsy didn't evidence any sign of extra mandibular disease. Biopsies taken from the ovary at ovarian cortex retrieval informed of lymphocytic cell infiltration. The immunophenotype revealed a CD19+, CD20+, CD222+, CD10+, HLADR+, CD38+, cytoplasmatic IgM+, CD45+ and Ig Kappa+, all this suggesting a Burkitt's Lymphoma diagnosis. FISH study revealed a c-MYC rearrangement. Reintroduction of the ovarian tissue was discarded. The patient underwent 6 months of chemotherapy, becoming amenorrheic. Eight months after surgery, the patient resumed menstrual cycles and despite a drop of AMH dropped from 9,8 pM (15th month) to 3 pM (28th month) she became pregnant spontaneously 34 months after surgery. Conclusion In Burkitt's Lymphoma, neoplastic involvement of the ovary can be present even in the absence of abdominal macroscopic signs of disease. An intraoperatory biopsy can be used in order to minimize the risk of misdiagnosing an ovarian metastasis but safer fertility preservation options such as oocyte/embryo cryopreservation must be considered when there is time before chemotherapy.
Anti-apoptotic effects of quercetin on ionizing radiation induced apoptosis in ovarian follicles
The aim of this study was to evaluate the anti-apoptotic effects of quercetin (QE) on ionized radiation (Rd) induced apoptosis in ovarian follicles. Analysis of mice ovary after exposure to Rd by TUNEL showed that there were apoptotic cells both in the follicular wall and the antrum, and that the number of follicles showing early atresic features was high in 3 hr after Rd. On the other hand, analysis of mice ovary 12 hr after exposure to Rd showed that the number of follicles containing apoptotic cells with advanced atresic features was significantly higher than the 3 hr after Rd group. The PCNA-positive granulosa cells were decreased in association with follicular atresia. The groups given treatment were observed to have some benefit from QE against the damage caused by Rd. The results of this study demonstrate that QE prevent follicular atresia in Rd induced apoptosis on ovarian follicles. Key words ionizing radiation, ovarian follicles, quercetin, TUNEL, PCNA
